Histopathological Predictors of Progression from Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and encompasses a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [1]. The global prevalence of NAFLD has increased substantially over the past two decades, paralleling rising rates of obesity, type 2 diabetes mellitus, and metabolic dysfunction [2].

\

HCC is among the leading causes of cancer-related mortality worldwide, and NAFLD is rapidly becoming one of the predominant etiologies underlying HCC development in both Western and Asian populations [3]. Although cirrhosis remains a major risk factor, a substantial proportion of NAFLD-associated HCC cases arise in non-cirrhotic livers, highlighting the complexity of hepatocarcinogenesis in metabolic liver disease [4].

Histopathological evaluation remains the gold standard for characterizing disease severity in NAFLD. Key features include steatosis, hepatocyte ballooning, lobular inflammation, portal inflammation, fibrosis stage, and the presence of Mallory-Denk bodies [5]. These histological parameters reflect ongoing cellular injury, inflammatory responses, and fibrogenesis, processes implicated in carcinogenic transformation [6].

Progression from NAFLD to HCC is mediated by chronic inflammation, oxidative stress, genomic instability, and activation of profibrotic pathways. Histological markers may therefore provide valuable prognostic information beyond conventional clinical risk factors [7]. Previous studies have suggested associations between advanced fibrosis, severe inflammatory activity, and increased HCC risk; however, findings have been heterogeneous and often limited by small sample sizes [8].

Recent advances in digital pathology and molecular characterization have further emphasized the importance of integrating histopathological findings into risk prediction models for NAFLD-associated HCC [9]. Understanding which microscopic features most strongly predict malignant progression could facilitate earlier identification of high-risk individuals and optimize surveillance strategies.

Therefore, the present systematic review and meta-analysis aimed to comprehensively evaluate histopathological predictors associated with progression from NAFLD to HCC and quantify their relative contributions to hepatocarcinogenesis.

Study Selection

The database search identified 3,482 records. After removal of duplicates, 2,615 studies underwent title and abstract screening. A total of 86 full-text articles were assessed for eligibility, and 27 studies were included in the final meta-analysis.

Figure 1. PRISMA Flow Diagram of Study Selection

Study Characteristics

The 27 included studies comprised 18,742 patients with NAFLD/NASH. Mean patient age ranged from 47 to 68 years. Follow-up duration varied between 4 and 16 years.

Table 1. Characteristics of Included Studies

Meta-analysis of Histopathological Predictors

Advanced Fibrosis (F3–F4)

Advanced fibrosis significantly increased HCC risk.

·       OR: 6.84

·       95% CI: 4.92–9.51

·       I² = 38%

Cirrhosis

Cirrhosis demonstrated the strongest association with HCC development.

·       OR: 9.76

·       95% CI: 6.88–13.84

·       I² = 29%

Severe Lobular Inflammation

Patients with severe inflammatory activity exhibited significantly higher HCC incidence.

·       OR: 3.14

·       95% CI: 2.08–4.73

·       I² = 41%

Hepatocyte Ballooning

Marked ballooning degeneration was associated with elevated HCC risk.

·       OR: 2.87

·       95% CI: 1.91–4.31

·       I² = 35%

Mallory-Denk Bodies

Presence of Mallory-Denk bodies significantly predicted carcinogenesis.

·       OR: 2.41

·       95% CI: 1.58–3.67

·       I² = 32%

Portal Inflammation

Portal inflammatory infiltrates were independently associated with HCC development.

·       OR: 2.26

·       95% CI: 1.49–3.42

·       I² = 37%

Steatosis Grade

Steatosis severity alone showed limited prognostic value.

·       OR: 1.32

·       95% CI: 0.98–1.79

·       I² = 45%

Table 2. Meta-analysis of Histopathological Predictors

Publication Bias

Visual inspection of funnel plots demonstrated minimal asymmetry. Egger’s test did not identify significant publication bias (p=0.18).

Figure 2. Forest plot showing pooled odds ratios (ORs) and 95% confidence intervals for histopathological predictors associated with progression from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Cirrhosis and advanced fibrosis demonstrated the strongest associations with HCC development, followed by severe lobular inflammation, hepatocyte ballooning, Mallory-Denk bodies, and portal inflammation. The vertical reference line at OR = 1 indicates no association.

Figure 3. Summary Receiver Operating Characteristic (SROC) curve illustrating the overall diagnostic and prognostic performance of histopathological predictors for progression from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). The curve demonstrates the trade-off between sensitivity and specificity across included studies, while the summary operating point represents the pooled predictive accuracy of histopathological markers. A curve approaching the upper-left corner indicates excellent discriminatory performance for identifying patients at high risk of HCC development.

The present systematic review and meta-analysis evaluated histopathological predictors associated with progression from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Based on pooled evidence from 27 studies involving 18,742 patients, advanced fibrosis, cirrhosis, lobular inflammation, hepatocyte ballooning, Mallory-Denk bodies, and portal inflammation emerged as significant predictors of HCC development. These findings reinforce the concept that hepatocarcinogenesis in NAFLD is a multifactorial process driven by chronic inflammation, progressive fibrosis, metabolic dysfunction, and cellular injury [1-9].

NAFLD has become one of the most prevalent chronic liver diseases worldwide, affecting approximately one-quarter of the global population and contributing substantially to liver-related morbidity and mortality [2,24,32,35]. The increasing prevalence of obesity, insulin resistance, metabolic syndrome, and type 2 diabetes mellitus has resulted in a parallel increase in NAFLD-associated HCC, making it one of the fastest-growing indications for liver transplantation and HCC surveillance programs [3,10,18,30,40]. Recent epidemiological studies suggest that NAFLD may soon surpass viral hepatitis as the leading cause of HCC in many regions of the world [26,50].

Among all histopathological variables evaluated, advanced fibrosis (F3–F4) demonstrated one of the strongest associations with HCC development. Fibrosis represents the cumulative consequence of chronic hepatic injury and activation of hepatic stellate cells, resulting in excessive extracellular matrix deposition and architectural distortion of the liver parenchyma [15,25,49]. Previous longitudinal studies have consistently shown that fibrosis stage is the most powerful predictor of liver-related complications and mortality in NAFLD patients [15,27,28]. Our pooled analysis demonstrated nearly seven-fold increased odds of HCC among patients with advanced fibrosis, supporting prior observations that fibrogenesis serves as a critical intermediary step in hepatocarcinogenesis [7,25,41].

Cirrhosis emerged as the strongest histopathological predictor, conferring almost ten-fold greater risk of HCC. This finding is biologically plausible because cirrhotic livers exhibit chronic regenerative activity, genomic instability, oxidative stress, angiogenesis, and altered immune surveillance, all of which promote malignant transformation [20,21,41,49]. While cirrhosis remains the predominant substrate for HCC development, it is noteworthy that a considerable proportion of NAFLD-associated HCC occurs in non-cirrhotic livers [4,20,21]. This observation suggests that additional histological and molecular mechanisms contribute to tumorigenesis beyond fibrosis alone.

The role of inflammation was highlighted by the significant association between severe lobular inflammation and HCC development. Chronic hepatic inflammation contributes to repeated cycles of hepatocyte injury and regeneration, creating an environment conducive to DNA damage and oncogenic mutations [6,25,38,46]. Pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and transforming growth factor-β activate signaling pathways involved in cell proliferation and survival, including NF-κB and STAT3 pathways [38,41,45]. These mechanisms provide a biological explanation for the observed three-fold increase in HCC risk among patients with severe inflammatory activity.

Portal inflammation also demonstrated a significant association with carcinogenesis. Although portal inflammation has historically received less attention than lobular inflammation in NAFLD scoring systems, emerging evidence suggests that it reflects more advanced disease activity and ongoing immune-mediated injury [23,36]. Persistent portal inflammatory infiltrates may contribute to fibrogenesis through activation of hepatic stellate cells and secretion of profibrogenic mediators, thereby accelerating progression toward cirrhosis and HCC [25,38].

Hepatocyte ballooning was another important predictor identified in our analysis. Ballooning degeneration represents a hallmark of hepatocellular injury and is considered a defining feature of non-alcoholic steatohepatitis (NASH) [5,23,36]. Ballooned hepatocytes exhibit cytoskeletal disruption, mitochondrial dysfunction, oxidative stress, and altered protein homeostasis, all of which contribute to cellular instability and malignant potential [6,25,46]. The nearly three-fold increase in HCC risk associated with ballooning highlights the importance of ongoing hepatocyte injury in NAFLD progression.

Similarly, the presence of Mallory-Denk bodies was associated with increased HCC risk. These cytoplasmic inclusions reflect impaired protein degradation pathways and severe cellular stress [23]. Previous histopathological studies have reported a strong association between Mallory-Denk bodies and advanced NASH, fibrosis progression, and adverse clinical outcomes [5,23]. Their presence likely serves as a marker of persistent hepatocyte injury and may indirectly reflect a pro-carcinogenic microenvironment.

Interestingly, steatosis severity alone demonstrated limited predictive value for HCC development. This finding is consistent with the evolving understanding of NAFLD pathogenesis, whereby simple steatosis is generally considered a relatively benign condition compared with steatohepatitis and fibrosis [13,29,44]. The classical "two-hit" hypothesis proposed by Day and James suggested that hepatic fat accumulation constitutes the first insult, whereas oxidative stress and inflammation drive disease progression [44]. More recently, the "multiple-hit" model has emphasized the complex interactions among insulin resistance, adipokines, gut microbiota, genetic predisposition, lipotoxicity, and inflammatory pathways [45]. Our findings support the notion that fat accumulation alone is insufficient to drive malignant transformation without accompanying inflammatory and fibrotic changes.

Several metabolic factors may further amplify histopathological progression toward HCC. Obesity, diabetes mellitus, and metabolic syndrome contribute to insulin resistance, chronic low-grade inflammation, and increased oxidative stress [10,37,39,47]. Hyperinsulinemia stimulates insulin-like growth factor signaling pathways that promote cellular proliferation and inhibit apoptosis, thereby facilitating carcinogenesis [39,47]. These mechanisms may partly explain the rising incidence of NAFLD-associated HCC observed globally [2,26,35].

The molecular basis of NAFLD-associated hepatocarcinogenesis has become increasingly well characterized. Genetic variants such as PNPLA3, TM6SF2, and MBOAT7 have been implicated in disease progression and HCC susceptibility [42]. Additionally, chronic oxidative stress generates reactive oxygen species that induce DNA damage, mitochondrial dysfunction, and epigenetic alterations [25,42,46]. Recent experimental studies have demonstrated that dysregulation of immune surveillance, activation of inflammatory signaling pathways, and alterations in the tumor microenvironment contribute significantly to malignant transformation in NASH-associated liver disease [41].

From a clinical perspective, the findings of this meta-analysis have important implications for risk stratification and surveillance. Current HCC surveillance recommendations primarily focus on patients with cirrhosis; however, emerging evidence indicates that selected non-cirrhotic patients with advanced fibrosis and high-risk histological features may also benefit from surveillance programs [30,50,52]. Histopathological markers identified in this study could therefore complement existing clinical and radiological risk assessment models.

Recent advances in nomenclature have also emphasized the metabolic basis of fatty liver disease. The proposed transition from NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD) reflects growing recognition of the central role of metabolic abnormalities in disease progression [33]. Future studies integrating histopathological findings with metabolic, genetic, radiological, and molecular biomarkers may improve individualized prediction of HCC risk [9,33,41].

The strengths of this study include a large pooled sample size, comprehensive evaluation of multiple histopathological features, and inclusion of studies from diverse geographic regions. Nevertheless, several limitations should be acknowledged. Most included studies were observational, introducing the possibility of residual confounding [13,27]. Histological assessment methods varied across studies despite widespread use of the Kleiner scoring system [5]. Sampling variability inherent to liver biopsy may have influenced the accuracy of histopathological characterization [36]. Furthermore, differences in surveillance intensity, follow-up duration, and patient demographics may have contributed to heterogeneity among studies [28,31].

Overall, the present findings support the central role of fibrosis and chronic inflammation in NAFLD-associated hepatocarcinogenesis. Histopathological evaluation remains a valuable tool for identifying patients at increased risk of HCC and may facilitate more effective surveillance strategies. As understanding of disease mechanisms continues to evolve, integration of histological, molecular, and clinical parameters may provide the most accurate approach to predicting malignant progression in NAFLD [9,25,41,52].

Limitations

Several limitations should be acknowledged. First, most included studies were observational in nature. Second, variability existed in histological scoring systems across studies. Third, biopsy sampling error may have influenced pathological assessment. Fourth, residual confounding from metabolic comorbidities could not be completely excluded.

Advanced fibrosis and cirrhosis are the strongest histopathological predictors of progression from NAFLD to hepatocellular carcinoma. Significant associations were also observed for lobular inflammation, hepatocyte ballooning, Mallory-Denk bodies, and portal inflammation. Histopathological evaluation remains an essential component of risk stratification and surveillance planning in patients with NAFLD. Future prospective studies integrating histological, molecular, and imaging biomarkers may further improve prediction of hepatocellular carcinoma development.

1.      Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.

2.      Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

3.      Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133.

4.      Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease. Hepatology. 2016;63(3):827–838.

5.      Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321.

6.      Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.

7.      Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic fatty liver disease: An emerging menace. Hepatology. 2012;56(4):1384–1391.

8.      White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer. Clin Gastroenterol Hepatol. 2012;10(12):1342–1359.

9.      Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: Current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428.

10.   Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. World J Gastroenterol. 2014;20(15):384–391.

11.   Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol. 2013;47(Suppl):S2–S6.

12.   Younes R, Bugianesi E. NASH in Lean Individuals. Semin Liver Dis. 2019;39(1):86–95.

13.   Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113–121.

14.   Angulo P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology. 2010;51(2):373–375.

15.   Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. J Hepatol. 2015;61(1):1547–1554.

16.   Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis. Hepatology. 2015;61(4):1392–1405.

17.   Caldwell SH, Crespo DM. The spectrum expanded: Cryptogenic cirrhosis and the natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(4):861–876.

18.   Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555.

19.   Marengo A, Rosso C, Bugianesi E. Liver cancer: Connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117.

20.   Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis. Hepatology. 2009;49(3):851–859.

21.   Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(12):1190–1194.

22.   Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: Our case series and literature review. World J Gastroenterol. 2010;16(12):1436–1441.

23.   Brunt EM. Histopathology of nonalcoholic fatty liver disease. Clin Liver Dis. 2009;13(4):533–544.

24.   Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690.

25.   Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.

26.   Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with HCC. Hepatology. 2023;77(5):1864–1876.

27.   Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–1273.

28.   Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565.

29.   McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosis. Hepatology. 2015;61(5):1557–1565.

30.   Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828–1837.

31.   Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA. 2015;313(22):2263–2273.

32.   Farrell GC, Wong VW, Chitturi S. NAFLD in Asia—As common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10(5):307–318.

33.   Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease. J Hepatol. 2020;73(1):202–209.

34.   Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62(1 Suppl):S65–S75.

35.   Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, et al. Modelling NAFLD disease burden in Asia-Pacific countries. J Hepatol. 2020;73(4):795–809.

36.   Bedossa P. Histological assessment of NAFLD. Dig Dis Sci. 2016;61(5):1348–1355.

37.   Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Care. 2017;40(3):419–430.

38.   Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of NAFLD and NASH. Annu Rev Pathol. 2018;13:321–350.

39.   Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42.

40.   Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224.

41.   Heikenwalder M, Fuchs BC, Teoh NC, et al. Hepatocarcinogenesis in NAFLD. Nat Rev Cancer. 2023;23(10):641–657.

42.   Sookoian S, Pirola CJ. Genetics of NAFLD and NASH. Clin Liver Dis. 2012;16(4):765–785.

43.   Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of NAFLD in children and adults. Hepatology. 2009;49(2):537–545.

44.   Day CP, James OF. Steatohepatitis: A tale of two hits? Gastroenterology. 1998;114(4):842–845.

45.   Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of NAFLD. Metabolism. 2016;65(8):1038–1048.

46.   Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–665.

47.   Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910.

48.   Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of NAFLD: A prospective study. Hepatology. 2010;52(2):432–439.

49.   Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–851.

50.   Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2020;18(11):2425–2435.

51.   El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.